Insights On CONTRACT PHARMA MANUFACTURING

  1. Modified Release Tablets: Strategies For Optimising Drug Delivery 1/29/2026

    Modified‑release tablets control drug release to improve treatment effectiveness, reduce side effects, and enhance patient adherence.

  2. Solving Four Challenges In Development With Scale-Out Manufacturing 1/28/2026

    Scale-out biomanufacturing enhances flexibility, speeds timelines, lowers risk, and enables efficient parallel production for scalable, resilient biologics and advanced therapies.

  3. From Fed-Batch To Continuous: How Perfusion Enables Smarter Biologics Production 1/28/2026

    Growing biologics demand is driving interest in perfusion culture as a complementary manufacturing strategy that enables continuous nutrient control, higher productivity, and performance when paired with fed-batch processes.

  4. A Trusted New Partnership 1/28/2026

    Optima delivers high‑quality, flexible syringe and vial filling solutions with fast qualification, U.S.‑based support, and long‑term partnership reliability, helping CDMOs scale efficiently and confidently.

  5. Handling Demanding Active Ingredients Safely And Efficiently 1/27/2026

    See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.

  6. Selecting A CDMO For Custom Activated PEGs 1/27/2026

    Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

  7. Commercially Proven Sterile Fill/Finish With Capacity And Global Backing 1/27/2026

    Find comprehensive solution with new sterile fill/finish investments supporting complex molecules through robust tech transfer, commercialization expertise, and integrated cGMP manufacturing solutions.

  8. PCI Pharma Services Capabilities Update January 2026: Fill/Finish 1/27/2026

    Patricia Krainski highlights PCI’s global sterile fill‑finish and lyophilization strengths, showcasing investments that expand capacity, technologies, and integrated solutions for complex biologics, formulations, and lyophilized products.

  9. Afton Scientific Capabilities Update January 2026: Fill/Finish 1/27/2026

    Here, Michael Dunn outlines our current available capacity, including RABS operations, alongside the commissioning of a new Annex 1–compliant isolator filling line and expanded QC capabilities to ensure reliable, scalable execution.

  10. Emerging Trends and Opportunities in Inhaled Biologics 1/26/2026

    Inhaled biologics are advancing as better formulations, particle design, and devices enable targeted delivery. Tracking key trends helps teams manage complexity and advance future therapies.